Patents Assigned to Boryung Pharmaceutical Co. Ltd.
  • Patent number: 10420728
    Abstract: Disclosed is a method for preparing a tablet. The method can improve the compressibility of the active ingredients and produce tablets of uniform quality, bringing about the advantage of increasing tablet hardness with an increase in compression pressure, easily controlling disintegration time, and decreasing tablet friability by using the active ingredient fimasartan, a pharmaceutically acceptable salt thereof or a hydrate or solvate thereof having a specific particle size distribution.
    Type: Grant
    Filed: January 11, 2016
    Date of Patent: September 24, 2019
    Assignee: Boryung Pharmaceutical Co., Ltd.
    Inventors: Jayhyuk Myung, Sung Chan Jeong, Yun Sam Kim
  • Publication number: 20180015043
    Abstract: Disclosed is a method for preparing a tablet. The method can improve the compressibility of the active ingredients and produce tablets of uniform quality, bringing about the advantage of increasing tablet hardness with an increase in compression pressure, easily controlling disintegration time, and decreasing tablet friability by using the active ingredient fimasartan, a pharmaceutically acceptable salt thereof or a hydrate or solvate thereof having a specific particle size distribution.
    Type: Application
    Filed: January 11, 2016
    Publication date: January 18, 2018
    Applicant: Boryung Pharmaceutical Co., Ltd
    Inventors: Jayhyuk Myung, Sung Chan Jeong, Yun Sam Kim
  • Patent number: 9592233
    Abstract: Provided is a pharmaceutical combination preparation including fimasartan and rosuvastatin as active ingredients together with meglumine. The combination preparation exhibits an outstanding effect in treating cardiovascular disease by improving the disintegration and the dissolution which obtained better drug bioavailability and drug safety.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: March 14, 2017
    Assignee: Boryung Pharmaceutical Co., Ltd.
    Inventors: Jayhyuk Myung, Kyung Wan Nam, Cheol Woo Lee, Ju Won Kim
  • Patent number: 9457094
    Abstract: The present invention provides: a pharmaceutical composition having a superior physical property since fimasartan and hydrochlorothiazide, which are main components of a combination preparation, have superior content uniformity; and a preparation method thereof.
    Type: Grant
    Filed: April 30, 2013
    Date of Patent: October 4, 2016
    Assignee: Boryung Pharmaceutical Co., Ltd.
    Inventors: Je Hak Kim, Kyung Wan Nam, Seo Hun Park, Ju Won Kim, Sang Yeop Kim
  • Publication number: 20160022679
    Abstract: The present invention relates to a pharmaceutical combination preparation comprising fimasartan and rosuvastatin as active ingredients together with meglumine. The combination preparation of the present invention exhibits an outstanding effect in treating cardiovascular disease by improving the disintegration and the dissolution which obtained better drug bioavailability and drug safety.
    Type: Application
    Filed: March 14, 2014
    Publication date: January 28, 2016
    Applicant: Boryung Pharmaceutical Co., Ltd.
    Inventors: Jayhyuk MYUNG, Kyung Wan NAM, Cheol Woo LEE, Ju Won KIM
  • Patent number: 9227955
    Abstract: Disclosed are an anti-angiogenic compound, represented by Chemical Formula I, or a pharmaceutically acceptable salt thereof, a preparation method thereof, and a pharmaceutically acceptable composition including the same. Because the compound of Chemical Formula I potently suppresses the angiogenesis, the compound of Chemical Formula I is applicable to the prevention and treatment of diseases caused by aberrant activity of vascular endothelial growth factor, and available as an anti-angiogenic agent.
    Type: Grant
    Filed: July 27, 2012
    Date of Patent: January 5, 2016
    Assignee: Boryung Pharmaceutical Co., Ltd.
    Inventors: Ji Han Kim, Je Hak Kim, Joon Kwang Lee, Hahn-Sun Jung, Nam Seok Han, Yong Park, Seung-Hoon Kang, Hee Jin Jeong, Kyung-Tae Lee, Hye Eun Choi, Yong Ha Chi, Joo Han Lee, Soo Heui Paik
  • Publication number: 20140256711
    Abstract: Disclosed are an anti-angiogenic compound, represented by Chemical Formula I, or a pharmaceutically acceptable salt thereof, a preparation method thereof, and a pharmaceutically acceptable composition including the same. Because the compound of Chemical Formula I potently suppresses the angiogenesis, the compound of Chemical Formula I is applicable to the prevention and treatment of diseases caused by aberrant activity of vascular endothelial growth factor, and available as an anti-angiogenic agent.
    Type: Application
    Filed: July 27, 2012
    Publication date: September 11, 2014
    Applicant: Boryung Pharmaceutical Co., Ltd.
    Inventors: Ji Han Kim, Je Hak Kim, Joon Kwang Lee, Hahn-Sun Jung, Nam Seok Han, Yong Park, Seung-Hoon Kang, Hee Jin Jeong, Kyung-Tae Lee, Hye Eun Choi, Yong Ha Chi, Joo Han Lee, Soo Heui Paik
  • Patent number: 8765776
    Abstract: Provided is an antihypertensive pharmaceutical composition containing Fimasartan, a pharmaceutically acceptable salt thereof, a solvate thereof or a hydrate thereof as an angiotensin II receptor blocker, and Amlodipine, an isomer thereof, a pharmaceutically acceptable salt thereof, a solvate thereof or a hydrate thereof as a calcium channel blocker.
    Type: Grant
    Filed: August 8, 2011
    Date of Patent: July 1, 2014
    Assignee: Boryung Pharmaceutical Co., Ltd.
    Inventors: Seung Ho Kim, Ji Han Kim, Je Hak Kim, Kyung Wan Nam, Yong Ha Chi, Joo Han Lee, Soo Heui Paik, So Jeong Yi, Tae Eun Kim, Seo Hyun Yoon, Joo Youn Cho, Sang Goo Shin, In Jin Jang, Kyung Sang Yu
  • Publication number: 20140044784
    Abstract: Disclosed is a combined formulation for oral administration to treat cardiovascular disease, including (a) cholesterol lowering agent mini-tablet having a diameter of 7.5 mm or less, which contain a cholesterol lowering agent, a stabilizer thereof and a pharmaceutically acceptable excipient and have a coating layer on the surface thereof, and (b) antithrombotic agent mini-tablets or mini-pellets having a diameter of 7.5 mm or less, which contain an antithrombotic agent and a pharmaceutically acceptable excipient and include an enteric coating film on the surface thereof. This formulation can improve treatment compliance depending on a combination prescription, and is controlled so that the cholesterol lowering agent is released in the gastrointestinal tracts and the antithrombotic agent is released in the intestines, thus suppressing the reactions and the side-effects between the drugs, inducing synergic effects of these drugs in vivo, and achieving improved stability.
    Type: Application
    Filed: March 14, 2012
    Publication date: February 13, 2014
    Applicant: BORYUNG PHARMACEUTICAL CO., LTD
    Inventors: Je Hak Kim, Kyung Wan Nam, Ju Won Park
  • Patent number: 8003850
    Abstract: Provided is a method for producing a target protein via cultivation of transgenic plant cells comprising a promoter capable of expressing the protein under sugar-free conditions in the response to the depletion of sugar and a gene encoding the target protein, without exchange of a cell growth medium with a sugar-depleted medium comprising the addition of an amino acid mixture to the sugar-rich medium used to grow the plant cells.
    Type: Grant
    Filed: September 19, 2007
    Date of Patent: August 23, 2011
    Assignee: Boryung Pharmaceutical Co., Ltd.
    Inventors: Sang-Lin Kim, Hyun-Kwang Tan, Sang-Min Lim, Wuk-Sang Ryu, Hahn-Sun Jung, Song-Jae Lee, Cheon-Ik Park, Seung-Hoon Kang, Dong-Il Kim
  • Publication number: 20100189717
    Abstract: The present invention provides a recombinant vector pBI-3D-hGalT or pBI-35S-hGalT containing a human ?1,4-galactosyltransferase gene; a cell line transformed with a recombinant vector pMYN414 containing a cytotoxic T-lymphocyte anti-gen A-immunoglobulin (CTLA4Ig) fusion protein gene and the recombinant vector pBI-3D-hGalT or pBI-355-hGalT; and a method for producing a plant-derived recombinant human CTLA4Ig (CTLA4Igp) fusion protein with a human glycan structure using the same. The plant cell-derived recombinant human CTLA4Ig fusion protein (CTLA4Igp), which has a human glycan structure and is produced according to the present invention, exhibits an improved in vivo half life as compared to conventional plant-derived proteins, due to the presence of a human-like glycan structure.
    Type: Application
    Filed: July 9, 2008
    Publication date: July 29, 2010
    Applicant: Boryung Pharmaceutical Co., Ltd.
    Inventors: Sang-Lin Kim, Hyun-Kwang Tan, Sang-Min Lim, Wuk-Sang Ryu, Hahn-Sun Jung, Song-Jae Lee, Cheon-Ik Park, Seung-Hoon Kang, Dong Il Kim
  • Publication number: 20090181428
    Abstract: Provided is a method for producing a target protein via cultivation of transgenic plant cells comprising a promoter capable of expressing the protein under sugar-free conditions or in response to the depletion of sugar and a gene encoding the target protein, without exchange of a cell growth medium with a sugar-depleted medium. The method comprises 1) culturing transgenic plant cells in a sugar-rich medium to grow plant cells; and 2) culturing the transgenic plant cells with addition of an amino acid mixture to the culture of Step 1 without exchange of a cell growth medium with a sugar-depleted medium, thereby expressing a target protein.
    Type: Application
    Filed: September 19, 2007
    Publication date: July 16, 2009
    Applicant: BORYUNG PHARMACEUTICAL CO., LTD.
    Inventors: Sang-Lin Kim, Hyun-Kwang Tan, Sang-Min Lim, Wuk-Sang Ryu, Hahn-Sun Jung, Song-Jae Lee, Cheon-Ik Park, Seung-Hoon Kang, Dong-Il Kim
  • Patent number: 7485656
    Abstract: An antibacterial composition for external application, particularly, a remedial formulation for external use containing fluconazole is disclosed. The formulation comprises a base material, 0.1-5.0 percent by weight of fluconazole and 1.0-40.0 percent by weight of any one compound selected from a group consisting of fatty acid, fatty alcohol, higher fatty acid ester and lower alcohol based on weight of the base material. The composition according to the present invention has various advantages of a favorable absorption into a system through the skin of a human body and delivery of active material into horny layer of the skin, a reduced skin stimulation and an excellent stability. Therefore, the composition is efficiently useable in a medical treatment application for dermatomycosis-related infectious diseases including tinea pedis, tinea corporis, tinea cruris, tinea versicolor and/or candidiasis and the like.
    Type: Grant
    Filed: February 7, 2002
    Date of Patent: February 3, 2009
    Assignee: Boryung Pharmaceutical Co., Ltd.
    Inventors: Sang-Lin Kim, Hyun-Kwang Tan, Jun-Sik Kim, Ho-Beom Lee, Geun-Hong Min, Hae-Won Ryou
  • Patent number: 7309788
    Abstract: A process for preparing pyrimidinone compound and salts thereof The method of the present invention enables the convenience to produce the pyrimidinone derivatives in high yields, which pyrimidinone compounds are useful for treating cardiovascular diseases caused by binding angiotensin II to its receptors, through antagonistic activity against angiotensin II receptors.
    Type: Grant
    Filed: September 21, 2001
    Date of Patent: December 18, 2007
    Assignee: Boryung Pharmaceutical Co., Ltd.
    Inventors: Sang-Lin Kim, Ji-Han Kim, Jung-Bok Lee, Byoung-Wug Yoo, Hyun-Kwang Tan
  • Patent number: 6294542
    Abstract: The present invention relates to a novel pyrimidinone compounds and the pharmaceutical acceptable salts thereof having remarkable antagonistic action against angiotensin II receptor, thereby, being useful in treating cardiovascular disease caused by binding angiotensin II to its receptor.
    Type: Grant
    Filed: December 20, 1999
    Date of Patent: September 25, 2001
    Assignee: Boryung Pharmaceutical Co. Ltd.
    Inventors: Jae-hyoung Lee, Kyung-jin Jang, Byoung-wug Yoo, Ji-han Kim, Jae-seog Kang, Sang-lin Kim
  • Patent number: 5869476
    Abstract: The invention relates to pyrimidinone derivatives and the pharmaceutically acceptable salts thereof having remarkable antagonistic action against angiotensin II receptor, and thus useful in treating cardiovascular diseases caused by angiotensin II.
    Type: Grant
    Filed: April 25, 1997
    Date of Patent: February 9, 1999
    Assignee: Boryung Pharmaceutical Co., Ltd.
    Inventors: Woo Hyun Paik, Ji Han Kim, Jae Hyoung Lee, Kyung Jin Jang, Kwang Jae Cho, Jae Seog Kang, Byoung Wug Yoo, Je Bum Park, Kyung Jin Kim, Kun Ja Lee
  • Patent number: 5739120
    Abstract: The present invention relates to new liponucleotide analog compounds having useful antiviral activity, represented by general formula (I): ##STR1## wherein R.sup.1 is a saturated or unsaturated alkyl having 6-22 C atoms; R.sup.2 is a saturated or unsaturated alkyl having 12-20 C atoms; R.sup.3 and R.sup.4 are each hydrogen or hydroxy; and B is one of the nucleoside bases of formula (a): ##STR2## wherein R.sup.5 is a hydrogen, halogen, hydroxy, amino, mercapto, or C.sub.1 -C.sub.4 alkyl amino; R.sup.6 is a hydrogen, halogen or amino; W is a nitrogen or C--R.sup.8 where R.sup.8 is hydrogen, halogen, amino or C.sub.1 -C.sub.4 alkyl, and pharmaceutically acceptable salts thereof.
    Type: Grant
    Filed: April 30, 1997
    Date of Patent: April 14, 1998
    Assignee: Boryung Pharmaceutical Co., Ltd.
    Inventors: Woo Hyun Paik, Won Sup Shin, Jae Seung Lee, Hee Sang Chai
  • Patent number: 4556516
    Abstract: A process for the preparation of acylureido penicillin derivatives is disclosed. In particular this invention concerns an economical process for the preparation with high yield of penicillin derivatives of the formula ##STR1## where R.sup.1 represents phenyl or hydroxyphenyl and R.sup.2 a member selected from the group consisting of hydrogen, a protecting group, sodium, potassium and calcium. The compounds are useful as anti-bacterial agents for human and animals.
    Type: Grant
    Filed: February 7, 1984
    Date of Patent: December 3, 1985
    Assignee: Boryung Pharmaceutical Co., Ltd.
    Inventor: Don K. Kim